Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 1.79M
Average 3.15M
Financial health
Rocket Pharmaceuticals, Inc. financial health
Start with the overall verdict and the rule-based risk checks for RCKT, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.
Cash & Investments
$145.72M
Debt Cushion
$120.96M
Current Ratio
6.1x
Interest Coverage
N/A
Risk checks
4 of 8 flagged
Interest covered
-45.7×
Passes when: Operating income is at least 1.5× interest expense
Debt repayable from cash flow
Negative FCF
Passes when: Free cash flow could repay all debt within 5 years
Stable Altman Z-Score
6.92 → -3.40
Passes when: Z-Score is not falling while below the 2.99 safe zone
Limited dilution
+14.9%/yr
Passes when: Diluted share count grows less than 2% a year
Positive equity
Positive
Passes when: Shareholders' equity is above zero
Short-term liquidity
6.1×
Passes when: Current assets are at least 1× current liabilities
Manageable net debt
Net cash
Passes when: Net debt is below 3× EBITDA
Tangible equity base
27.0%
Passes when: Goodwill and intangibles are below 50% of equity
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
Piotroski F-Score
Weak0 / 9
Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.
Altman Z-Score
Distress zone-2.53
Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$49.61M
Q1 2026
Quick Ratio
6.1x
Q1 2026
Current Ratio
6.1x
Q1 2026
Cash Ratio
2.0x
Q1 2026
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$24.76M
Q1 2026
Debt/Equity
0.1x
Q1 2026
Debt/Assets
0.1x
Q1 2026
Interest Coverage
—
Q1 2026
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$1.34M
Q1 2026
Assets
$285.41M
Q1 2026
Liabilities
$47.37M
Q1 2026
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q1 2026).
Competitor health
How does Rocket Pharmaceuticals, Inc. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
LB Pharmaceuticals Inc Common Stock LBRX:NASDAQ | $1.39B | 0.01 | 0.01 | 9.91 | — | 41.44 | 41.44 | 33.62 |
Solid Biosciences Inc. SLDB:NASDAQ | $763.42M | 0.12 | 0.09 | 0.22 | — | 6.14 | 6.14 | 1.79 |
Aura Biosciences, Inc. AURA:NASDAQ | $739.97M | 0.13 | 0.10 | 0.40 | — | 8.15 | 8.15 | 3.24 |
Design Therapeutics, Inc. DSGN:NASDAQ | $670.46M | 0.01 | 0.01 | 0.22 | — | 17.14 | 17.14 | 1.29 |
Annexon, Inc. ANNX:NASDAQ | $642.26M | 0.12 | 0.09 | 0.67 | — | 5.68 | 5.68 | 3.80 |
Autolus Therapeutics plc AUTL:NASDAQ | $311.41M | 1.97 | 0.60 | Net cash | — | 5.48 | 5.94 | 1.42 |
DBV Technologies S.A. DBVT:NASDAQ | $263.50M | 0.13 | 0.09 | 1.24 | — | 3.67 | 3.67 | 3.35 |
Quantum-Si incorporated QSI:NASDAQ | $229.78M | 0.02 | 0.02 | 0.18 | — | 7.50 | 7.64 | 0.94 |
Galectin Therapeutics Inc. GALT:NASDAQ | $200.86M | -1.06 | 6.85 | Net cash | — | 2.42 | 2.42 | 2.21 |
Questions
Financial health questions
Common questions about RCKT's balance sheet, answered from the reported figures.
Is RCKT's balance sheet healthy?
Rocket Pharmaceuticals, Inc. (RCKT) has a current ratio of 6.12, a quick read on short-term liquidity.
How leveraged is RCKT?
Debt to equity is 0.10, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.